2026-10-11T22:21:10Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33738475 2026-09-14T13:00:18Z category_696 portal_316 item_type_3 month_year_09_2026

Data Sheet 2_Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis.zip Qingqing Jiang (1391545) Zhengtian Gu (2949717) Genetic Immunology chronic inflammatory demyelinating polyradiculoneuropathy CIDP corticosteroids efgartigimod alfa FcRn inhibitors intravenous immunoglobulin network meta-analysis plasma exchange Background<p>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) management is undergoing a paradigm shift with the emergence of targeted biologicals. We aimed to compare the efficacy, safety, and functional outcomes of neonatal Fc receptor (FcRn) inhibitors against conventional immunotherapies.</p>Methods<p>We conducted a systematic review and frequentist network meta-analysis (NMA) of randomized controlled trials (RCTs) indexed in PubMed/MEDLINE, Embase, CENTRAL, Web of Science, ClinicalTrials.gov, and WHO ICTRP from database inception to February 2026. Interventions included FcRn inhibitors (efgartigimod alfa, rozanolixizumab), intravenous/subcutaneous immunoglobulin (IVIg/SCIG), corticosteroids, plasma exchange (PLEX), and rituximab. The primary outcome was clinical response rate. Secondary outcomes included serious adverse events (SAEs), discontinuation due to adverse events (DCAE), and grip-strength change as a distal motor outcome. Treatments were ranked using P-scores, and certainty of evidence was summarized using CINeMA/GRADE domains.</p>Findings<p>Eighteen RCTs (n=2,184) were included. In the primary efficacy network (I2 = 0.37%), PLEX (OR 33.60, 95% CI 3.15–358.90; P-score 0.9415) and corticosteroids (OR 15.44, 95% CI 3.53–67.47; P-score 0.9056) demonstrated the highest probability of achieving clinical response. Efgartigimod alfa showed significant clinical response (OR 3.14, 95% CI 1.34–7.33) and ranked highest for grip-strength change (SMD 0.67, 95% CI 0.09–1.24; P-score 0.8847), although this analysis was based on five studies and should be interpreted as a distal motor outcome rather than a comprehensive functional endpoint. For secondary outcomes, FcRn inhibitors had SAE estimates comparable to placebo (efgartigimod OR 1.00, 95% CI 0.31–3.20; rozanolixizumab OR 0.94, 95% CI 0.05–16.37), and rozanolixizumab ranked highest for DCAE/acceptability (P-score 0.7896). Heterogeneity was low to modest across secondary networks (SAEs I2 = 12.40%; DCAE I2 = 0.00%; grip strength I2 = 24.10%).</p>Interpretation<p>PLEX and corticosteroids showed the strongest relative effects for short-term clinical response, whereas efgartigimod alfa showed a significant treatment effect and the highest ranking for grip-strength change among studies reporting this distal motor measure. IVIg remains a broadly supported comparator across induction and maintenance settings. These findings should inform, but not replace, individualized clinical decision-making because patient-level treatment-effect modification, biomarker status, prior treatment response, and long-term neurophysiological outcomes were not directly evaluated.</p> 2026-09-14T13:00:18Z Dataset Dataset 10.3389/fimmu.2026.1856507.s001 https://figshare.com/articles/dataset/Data_Sheet_2_Comparative_efficacy_safety_and_functional_recovery_of_neonatal_fc_receptor_inhibitors_and_conventional_immunotherapies_for_chronic_inflammatory_demyelinating_polyradiculoneuropathy_a_systematic_review_and_network_meta-analysis/33738475 CC BY 4.0